LB-101 (Centessa Pharmaceuticals)

N/A

Report date: 2023/02/02 10:07:25

Base Information

Drug NameLB-101 (Centessa Pharmaceuticals)
Drug Alias NameLB-101 (Centessa Pharmaceuticals)LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Programmed death-ligand 1Anti-Cluster of differentiation 47
TargetsProgrammed death-ligand 1Cluster of differentiation 47
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCentessa Pharmaceuticals Plc
China Registration ClassN/A

Develop Information

Active CompaniesCentessa Pharmaceuticals Plc
Inactive CompaniesCentessa Pharmaceuticals (UK) LtdLockbody Therapeutics Ltd
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A